![Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications](https://www.degruyter.com/document/doi/10.1515/hsz-2016-0201/asset/graphic/j_hsz-2016-0201_fig_001.jpg)
Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications
![Biomolecules | Free Full-Text | Mechanisms of Alpha-Synuclein Action on Neurotransmission: Cell-Autonomous and Non-Cell Autonomous Role Biomolecules | Free Full-Text | Mechanisms of Alpha-Synuclein Action on Neurotransmission: Cell-Autonomous and Non-Cell Autonomous Role](https://www.mdpi.com/biomolecules/biomolecules-05-00865/article_deploy/html/images/biomolecules-05-00865-g001.png)
Biomolecules | Free Full-Text | Mechanisms of Alpha-Synuclein Action on Neurotransmission: Cell-Autonomous and Non-Cell Autonomous Role
![Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice | BMC Neuroscience | Full Text Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice | BMC Neuroscience | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2202-2-11/MediaObjects/12868_2001_Article_12_Fig2_HTML.jpg)
Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice | BMC Neuroscience | Full Text
![Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model | npj Parkinson's Disease Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model | npj Parkinson's Disease](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41531-018-0062-4/MediaObjects/41531_2018_62_Fig1_HTML.png)
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model | npj Parkinson's Disease
![Targeted attenuation of elevated histone marks at SNCA alleviates α‐ synuclein in Parkinson's disease | EMBO Molecular Medicine Targeted attenuation of elevated histone marks at SNCA alleviates α‐ synuclein in Parkinson's disease | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/81235932-5425-4bbf-b7de-ad3ad12b9f3a/emmm202012188-fig-0001-m.jpg)
Targeted attenuation of elevated histone marks at SNCA alleviates α‐ synuclein in Parkinson's disease | EMBO Molecular Medicine
![Frontiers | The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease Frontiers | The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease](https://www.frontiersin.org/files/Articles/580634/fcell-08-580634-HTML/image_m/fcell-08-580634-g001.jpg)
Frontiers | The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease
![The Relationship between Alpha-Synuclein (SNCA) Gene Polymorphisms and Development Risk of Parkinson's Disease | IntechOpen The Relationship between Alpha-Synuclein (SNCA) Gene Polymorphisms and Development Risk of Parkinson's Disease | IntechOpen](https://cdnintech.com/media/chapter/65009/1512345123/media/F1.png)
The Relationship between Alpha-Synuclein (SNCA) Gene Polymorphisms and Development Risk of Parkinson's Disease | IntechOpen
![IJMS | Free Full-Text | Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease IJMS | Free Full-Text | Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease](https://www.mdpi.com/ijms/ijms-21-03301/article_deploy/html/images/ijms-21-03301-g001-550.jpg)